In summary, we identify for the first time, to the best of our knowledge, ARNT/HIF‐1β as a potential biomarker for prediction of therapeutic response and prognosis of MM patients, especially those carrying high‐risk 1q21 gain. This evidence concerns the gene ARNT and Miyoshi myopathy.